Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine

NCT01696123 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
125
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Shahid Beheshti University of Medical Sciences